



Monitoring of phosphorylation using immobilized kinases by on-line enzyme bioreactors hyphenated with High-Resolution Mass Spectrometry

Justine Ferey, David da Silva, Cyril Colas, Pierre Lafite, Dimitrios Topalis, Vincent Roy, Luigi Agrofoglio, Richard Daniellou, Benoît Maunit

► To cite this version:

Justine Ferey, David da Silva, Cyril Colas, Pierre Lafite, Dimitrios Topalis, et al.. Monitoring of phosphorylation using immobilized kinases by on-line enzyme bioreactors hyphenated with High-Resolution Mass Spectrometry. *Talanta*, 2019, 205, pp.120120. 10.1016/j.talanta.2019.120120 . hal-03466045

HAL Id: hal-03466045

<https://hal.science/hal-03466045>

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Monitoring of phosphorylation using immobilized kinases by on-line enzyme bioreactors hyphenated with High-Resolution Mass Spectrometry

Justine Ferey^{1*}, David Da Silva¹, Cyril Colas^{1,2}, Pierre Lafite¹, Dimitrios Topalis³, Vincent Roy¹, Luigi A. Agrofoglio¹, Richard Daniellou¹, Benoît Maunit¹

¹ Univ. Orléans, CNRS, ICOA, UMR 7311, F-45067 Orléans, France.

² CNRS, CBM, UPR 4301, Univ-Orléans, F-45071, Orléans, France

³ Rega Institute for Medical Research, KU Leuven, Herestraat 49 – box 1043, 3000, Leuven, Belgium

• To whom correspondence should be addressed: Dr. Justine FERÉY,
justine.ferey@insa-rouen.fr

Address: Institut de Chimie Organique et Analytique (ICOA)

UMR-CNRS 7311

Université d'Orléans

Rue de Chartres

45067 Orléans cedex 02 – France

E-mail address: justine.ferey@insa-rouen.fr

Tel: +33 238492411

Fax: +33 238417281

Abstract

Nucleosides analogues are the cornerstone of the treatment of several human diseases. They are especially at the forefront of antiviral therapy. Their therapeutic efficiency depends on their capacity to be converted to the active nucleoside triphosphate form through successive phosphorylation steps catalyzed by nucleoside/nucleotide kinases. In this context, it is mandatory to develop a rapid, reliable and sensitive enzyme activity test to evaluate their metabolic pathways. In this study, we report a proof of concept to directly monitor on-line nucleotide multiple phosphorylation. The methodology was developed by on-line enzyme bioreactors hyphenated with High-Resolution Mass Spectrometry detection. Human Thymidylate Kinase (hTMPK) and human Nucleoside Diphosphate Kinase (hNDPK) were covalently immobilized on functionalized silica beads, and packed into micro-bioreactors (40

μL). By continuous infusion of substrate into the bioreactors, the conversion of thymidine monophosphate (dTMP) into its di- (dTDP) and tri-phosphorylated (dTTP) forms was visualized by monitoring their Extracted Ion Chromatogram (EIC) of their [M-H]⁻ ions. Both bioreactors were found to be robust and durable over 60 days (storage at 4°C in ammonium acetate buffer), after 20 uses and more than 750 minutes of reaction, making them suitable for routine analysis. Each on-line conversion step was shown rapid (< 5 min), efficient (conversion efficiency > 55 %), precise and repeatable (CV < 3% for run-to-run analysis). The feasibility of the on-line multi-step conversion from dTMP to dTTP was also proved. In the context of selective antiviral therapy, this proof of concept was then applied to the monitoring of specificity of conversion of two synthesized Acyclic Nucleosides Phosphonates (ANPs), regarding human Thymidylate Kinase (hTMPK) and *vaccina virus* Thymidylate Kinase (vvTMPK).

Keywords: Drug discovery, high resolution mass spectrometry, immobilized kinases, on-line enzymatic phosphorylation.

1. Introduction

Drug discovery is a lengthy process. To gain a better understanding of the activity and toxicity of pharmaceutical drugs, it is important to determine their metabolic pathways [1, 2]. The monitoring of conversion efficiency helps to optimize the drug development process. One illustration of this latter is the activation of nucleotide analogues into their triphosphate active form [3-5]. These compounds are the cornerstone of the treatment of several human diseases and are especially at the forefront of antiviral therapy [6-9]. Biological activities are exhibited by triphosphate nucleotides, which compete with natural substrates for incorporation in the newly synthesized DNA strand, thus causing the inhibition of viral polymerase activity (e.g.

DNA chain termination) and therefore virus replication [10, 11]. To ensure good stability and high availability, these compounds are delivered as uncharged molecules [12]. Two major antiviral nucleoside classes have proved to be biologically active: the nucleoside analogues [13] and the Acyclic Nucleoside Phosphonate (ANPs) analogues [7]. Since the rate-limiting step of the drug activation is the conversion of nucleoside analogues to their monophosphate form, nucleotide analogues as ANPs were designed to circumvent the initial phosphorylation activation step [14]. The phosphorylation process of a monophosphate to its triphosphate counterpart involves two successive enzymatic phosphorylation reactions catalyzed by cellular kinases [14, 15]. For instance, the conversion of the endogenous thymidine monophosphate (dTMP) to thymidine triphosphate (dTTP) is catalyzed by the human Thymidylate Kinase (hTMPK) and the human Nucleoside Diphosphate Kinase (hNDPK) [11]. This activation is performed by a phosphotransfer reaction from a donor, usually the γ -phosphate of adenosine-5'-triphosphate (ATP), towards an acceptor such as the 5'-OH nucleoside or α -, β -phosphate nucleotide groups, in the presence of a chelating agent (usually Mg^{2+}) [3-5, 16]. To the best of our knowledge, the main techniques used to determine the efficiency of a kinase catalyzed reaction are spectrophotometric [17-19], radioisotopic [20-22], High Performance Liquid Chromatography (HPLC) [23] and Capillary Electrophoresis (CE) [24-26]. Although all these techniques have shown their potential for the study of kinase activity, the development of an on-line mass spectrometric approach makes sense in view of its rapidity, substrate versatility and specificity of detection. These on-line methodologies are currently gaining interest for application in drug discovery [27-32]. This liquid chromatography methodology uses biological agents as stationary phase to study enzyme/ligand interactions [33]. Enzyme-immobilized bioreactors offer usually various advantages such as purification of the biological environment (low matrix effect), preservation of activity, bioreactor stability (possible reuse), ease of analysis, easy coupling

with the detection system, direct conversion monitoring and possible high throughput screening of compound mixtures. Recently, the use of on-line methodologies with a single bioreactor or multi-reactor have been presented in the field of substrate conversion monitoring [34, 35] or DNA digestion [36].

In this context, the present study aimed to develop a rapid, efficient and versatile on-line methodology for the direct monitoring of nucleoside monophosphate and nucleotide diphosphate phosphorylation. As a proof of concept, individual conversion of dTMP into dTDP and dTDP into dTTP were monitored by on-line infusion into immobilized hTMPK and hNDPK bioreactors. The feasibility of the on-line two successive phosphorylation steps was also evaluated. This on-line system showed various advantages such as a rapid (less than 5 minutes) and efficient (more than 50%) conversion. Moreover, thanks to the dual loop system, this system is versatile (successive substrate infusion) and automatable. It also allows to directly visualize the drug conversion with the specific detection by mass spectrometry. This developed on-line methodology was then applied to the qualitative study of specificity of conversion of two chemically synthesized Acyclic Nucleotides Phosphonates (ANPs) named ANP-CH₃ and ANP-Br [37] (molecular formula shown in Figure 1) regarding two TMPKs: *vaccina virus* TMPK (vvTMPK) and human TMPK (hTMPK).

2. Experimental section

2.1. Material

Thymidine 5'-monophosphate disodium salt hydrate (dTMP), thymidine 5'-diphosphate sodium salt (dTDP), thymidine 5'-triphosphate sodium salt (dTTP), adenosine 5'-triphosphate magnesium salt (ATP), ammonium acetate (AcNH₄) and magnesium chloride (MgCl₂) were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France). For each experiment, AcNH₄ was used at 50 mM ionic strength at pH = 7. The bioreactor (50 x 1 mm stainless steel

capillary), column end fitting, high pressure unions, back pressure regulator (500 psi) and PEEK tubing (1 mm and 0.75 mm) were purchased from Cluzeau Info Labo (Sainte-Foy-La-Grande, France). The de-ionized water used in all procedures was purified with an Elgastat UHQ II system (Elga, Antony, France). Plasmids bearing hTMPK, *vv*TMPK and recombinant hNDPK were a generous gift from the University Pierre et Marie Curie (UPMC-Paris 6). Recombinant hTMPK was produced and purified as previously described [38]. Acyclic nucleoside monophosphates ANP-CH₃-MP and ANP-Br-MP were synthesized as described in our previous work [37].

2.2. Instrumentation

Experiments were performed on a Bruker maXis UHR-Q-TOF spectrometer (Bremen, Germany) in negative ion mode. The mass spectrometer was coupled on-line with a Dionex UltiMate 3000 RSLC system (Germering, Germany). Before each experiment, calibration was performed using ES-TOF tuning mix (Agilent Technologies, Les Ulis, France). The capillary voltage was set at - 4000 V, the nebulizer pressure at 0.6 bar, the dry gas flow at 7.0 L min⁻¹ and heated at 200°C. Spectra were recorded within the mass range from m/z 50 to 1350. Chromatograms of the ions of interest (m/z 321.0500 [M-H]⁻ for dTMP, m/z 401.0166 [M-H]⁻ for dTDP and m/z 480.9831 [M-H]⁻ for dTTP, m/z 259.0562 [M-H]⁻ for ANP-CH₃-MP, m/z 322.0561 [M-H]⁻ for ANP-Br-MP, m/z 339.0150 [M-H]⁻ for ANP-CH₃-DP and m/z 402.0149 [M-H]⁻ for ANP-Br-DP) were generated as Extracted Ion Chromatograms (EIC) within a \pm 0.005 m/z range. m/z values are summarized in Table 1. All data were analyzed using DataAnalysis 4.4 software (Bruker).

2.3. Enzyme immobilization

hTMPK, *vv*TMPK and hNDPK immobilizations were performed following a previous study [39]. Briefly, separate immobilizations *via* glutaraldehyde cross-linking agent were performed

by placing the enzyme in contact with 30 mg of silica beads diluted in phosphate buffer (500 μL , 50 mM ionic strength, $\text{pH} = 7$) with final excess concentrations of 0.55 mg mL^{-1} of hTMPK and $\nu\nu$ TMPK and 1.8 mg mL^{-1} of hNDPK. The three solutions were stirred for 6 h at 4°C and then stored overnight with 1 mM glycine at 4°C. Remaining free hTMPK, $\nu\nu$ TMPK and hNDPK were removed by successive washings (AcNH_4).

2.4. Bioreactor packing

Each immobilized enzyme solution was placed in a tank (100 x 4.6 mm) connected to the bioreactor (50 x 1 mm) by means of a PEEK tube of 1 mm id and a true zero dead volume union. A frit was placed at the end of the bioreactor to retain the silica beads. AcNH_4 buffer was eluted through the tank with a semi-micro HPLC pump (PU-2085 Plus, Jasco, Tokyo, Japan). Start flow was set at 10 $\mu\text{L min}^{-1}$ and was gradually increased to reach a maximum pressure of 30 bar. After 1 h of elution, a back-pressure regulator was added at the end of the bioreactor. At the maximum pressure of 40 bar, silica was considered packed into the bioreactors. The bioreactor denaturation was performed by overnight MeOH infusion at 60 $\mu\text{L min}^{-1}$.

2.5. On-line fluidic system

As shown in Figure 2, the on-line system consisted in a high flow rate precision pump and a ten-port valve containing 2 injection loops connected to the bioreactors (active and denatured). AcNH_4 buffer was eluted at 40 $\mu\text{L min}^{-1}$ (or 60 $\mu\text{L min}^{-1}$) through the ten-port valve. On this valve, two 320 μL injection loops, build with 0.75 mm id PEEK tubes were placed in back flush configuration (Figure S1). Injections were made at position 7 by means of an autosampler. The autosampler injected 400 μL of a solution “1” into the loop 1 (position valve 1-2) with the loading pump. The valve then switches to position 1-10 to infuse solution “1” into the bioreactors with the analytical pump (AcNH_4 buffer). During loop 2 infusion, the

loop 1 is washed with AcNH₄ buffer and a solution “2” is loaded into the loop 2 with the loading pump (position valve 1-10). When the infusion is completed, the valve switches to position 1-2 and loop 2 is infused. Solutions “1” and “2” can be the same for a longer time infusion or can be different for a screening approach. Each parameter (time infusion, injection, valve position) is programmed manually in the method (script editor). The valve switched every 3 or 5 minutes (for flow rates of 60 $\mu\text{L min}^{-1}$ and 40 $\mu\text{L min}^{-1}$, respectively). The two bioreactors, joined in series at 37°C in an oven, are connected to the ten-port valve at position 4 from the inlet and directly linked to the electrospray source from the outlet.

2.6. Validation of the on-line methodology for individual or multi-step enzymatic reaction

2.6.1. hTMPK bioreactor conversion

The bioreactor was conditioned at 37°C by AcNH₄ buffer elution for 15 minutes at a flow rate of 60 $\mu\text{L min}^{-1}$. 400 μL of a 20 μM dTMP solution (AcNH₄, [ATP] = 150 μM , [MgCl₂] = 200 μM ,) were injected *via* the loop system as previously described. After the valve switch, the sample contained in the loop was eluted with AcNH₄ at a flow rate of 60 $\mu\text{L min}^{-1}$ (P = 10 bar) into the hTMPK bioreactor. During the first loop infusion, 400 μL of the same dTMP solution were injected into the second loop. After 3 minutes of infusion, the valve was switched to infuse the second loop. This process was repeated until the EIC plateau for dTMP and dTDP was reached. The bioreactor was then washed and the enzymes were regenerated with AcNH₄ at 100 $\mu\text{L min}^{-1}$ until elimination of the substrate and product from the capillary. Between each use, the hTMPK bioreactor was stored at 4°C in AcNH₄. The same methodology was applied to the vvTMPK bioreactor study.

2.6.2. hNDPK bioreactor conversion

The hNDPK bioreactor was conditioned as previously described. The dTDP solution (20 μ M in AcNH₄, [ATP] = 150 μ M, [MgCl₂] = 200 μ M) was continuously infused into the hNDPK bioreactor at a flow rate of 40 μ L min⁻¹ (5 minutes between each valve switch). Analyses were performed after dTDP and dTTP EIC plateau monitoring. The bioreactor was then washed and the enzymes were regenerated with AcNH₄ at 100 μ L min⁻¹ until elimination of the substrate and product. Between each use, the hNDPK bioreactor was stored at 4°C in AcNH₄.

2.6.3. Multi-step phosphorylation with hTMPK and hNDPK bioreactors in series

The bioreactors were placed in series *via* a stainless steel high-pressure union. 20 μ M dTMP solution ([ATP] = 150 μ M, [MgCl₂] = 200 μ M) was infused at 40 μ L min⁻¹ (P = 11 bar) as previously described (5 minutes between each valve switch). Analysis was stopped after monitoring the dTMP, dTDP and dTTP EIC plateaus. The bioreactors were washed and the enzymes were regenerated with ACNH₄ elution at 80 μ L min⁻¹.

2.6.4. Stability and reuse of the hTMPK and hNDPK bioreactors study

hTMPK bioreactor: 20 μ M dTMP solution ([ATP] = 150 μ M, [MgCl₂] = 200 μ M) was infused at 60 μ L min⁻¹ with AcNH₄ in the hTMPK bioreactor. Seven points of activity were recorded over 60 days. Over this period, the bioreactor was used 21 times, corresponding to 795 min of use. The hTMPK bioreactor was alternatively used and stored at 4°C in AcNH₄ for 60 days.

hNDPK bioreactor: 20 μ M dTDP solution ([ATP] = 150 μ M, [MgCl₂] = 200 μ M) was infused at 40 μ L min⁻¹ with AcNH₄ in the hNDPK bioreactor. Seven points of activity were recorded over 68 days (20 uses, corresponding time of use 915 minutes). The hNDPK bioreactor was alternatively used and stored in ammonium acetate buffer at 4°C for 68 days.

2.7. Application of the on-line methodology for the study of two ANPs specific conversion regarding hTMPK and ν TMPK

hTMPK and ν TMPK bioreactors were individually placed in the fluidic system as described in paragraph 2.6.1. The bioreactors were conditioned at 37°C with AcNH₄ buffer elution for 15 min at a flow rate of 60 μ L min⁻¹. 400 μ L of 20 μ M of each substrate solution (dTMP, ANP-CH₃-MP and ANP-Br-MP in AcNH₄, [ATP] = 150 μ M and [MgCl₂] = 200 μ M,) were injected via the loop system as previously described. Substrate solutions were continuously infused until the detection of EIC plateau. Between each substrate infusion, the bioreactors were washed and the enzymes were regenerated with AcNH₄ at 100 μ L min⁻¹ until elimination of substrate and product from the capillary.

3. Results and discussion

3.1. Monitoring phosphorylation – Optimization of the on-line methodology conditions

In this study, optimizations of the system were conducted. The phosphodonor and chelatatant concentrations were evaluated for the conversion efficiency and the fluidic system and the bioreactor packing (Figure S2) were optimized. The influence of [ATP] and [MgCl₂] on ionization and on the mono-phosphorylation step was evaluated in our previous study with the same enzymes [39]. The optimal concentration of the phosphodonor (ATP) for on-line conversion was evaluated for the first reaction step, using the hTMPK bioreactor. Based on the results shown in Figure S3, the optimum concentration was fixed at 150 μ M of ATP, in terms of conversion rate, conversion speed and detector saturation. This concentration was then fixed for the study of the hNDPK bioreactor.

The immobilization step was carried out with high enzymes concentrations in order to saturate the immobilization sites as described in our previous study [39]. Free and immobilized

enzyme activities were evaluated by FIA-HRMS. The immobilized enzyme activities were evaluated by Michaelis-Menten study by Flow Injection Analysis hyphenated with High Resolution Mass Spectrometry, as described in our last work [39]. Briefly, similar K_M values for immobilized and free enzymes were obtained regarding dTMP [$K_{M(\text{free hTMPK})} = 34.43 \pm 5.05 \mu\text{M}$, $K_{M(\text{immobilized hTMPK})} = 27.92 \pm 4.14 \mu\text{M}$ and $K_{M(\text{free hNDPK})} = 92.75 \pm 12.80 \mu\text{M}$, $K_{M(\text{immobilized hNDPK})} = 132.90 \pm 18.50 \mu\text{M}$], showing that the immobilization step does not influence the enzyme's affinity towards its substrate. The reaction speed (V_{max}) of the immobilized enzymes was reduced by half [$V_{\text{max}(\text{free hTMPK})} = 6.86 \pm 0.51 \mu\text{M min}^{-1}$, $V_{\text{max}(\text{immobilized hTMPK})} = 2.94 \pm 0.17 \mu\text{M min}^{-1}$ and $V_{\text{max}(\text{free hNDPK})} = 13.01 \pm 1.27 \mu\text{M min}^{-1}$, $V_{\text{max}(\text{immobilized hNDPK})} = 6.41 \pm 0.36 \mu\text{M min}^{-1}$]. Immobilized hTMPK and hNDPK activities were proved to be sufficient to evaluate on-line phosphorylation reactions. In this context, these enzymes were used for the on-line reactions studies.

As shown in Figure 2, the system consists of a dual injection loop (2 loops of 320 μL) connected to a ten-port valve. The volume of the two loops, arbitrarily fixed at 320 μL to obtain an elution time of 5 min for each one (flow rate fixed at 50 $\mu\text{L min}^{-1}$), is adjustable depending on the elution time required. This system provides a constant ligand infusion into the bioreactors with high versatility (no mobile phase changes or lengthy reconditioning between ligand analyses) and without LC system salt contamination. Ligand injection into the loop can be performed manually by means of a syringe (for method development) or by programming automatic injection *via* the use of a second pump and an autosampler. This automation makes the system compatible for routine analysis and for molecule screening. Each bioreactor was evaluated for one-step reaction in terms of feasibility, conversion rates, stability and analysis repeatability. For both bioreactors, each specific substrate (dTMP and dTDP) was infused into active and denatured hTMPK and hNDPK bioreactors respectively, to estimate false positive conversion detection and to evaluate non-specific interactions. The

feasibility of the on-line two successive phosphorylations was then evaluated before the application study.

3.2. Validation of the on-line approach for single step phosphorylation monitoring

3.2.1. hTMPK bioreactor

The conversion of nucleoside monophosphate into nucleoside diphosphate is known to be the reaction-limiting step [10, 14]. hTMPK bioreactor conversion was evaluated by natural substrate (dTMP) infusion. The reaction was directly checked by monitoring the specific EIC of the masses of interest. During the infusion step ($60 \mu\text{L min}^{-1}$) the substrate first bound to the enzyme. After full saturation of the active sites, dTMP passed through the bioreactor and the EIC related to the non-retained substrate appeared. The product was then released from the bioreactor and the dTDP EIC was delayed. Figure 3 shows the EIC of dTMP and dTDP during the infusion of dTMP solution into the denatured and active bioreactor. No conversion was achieved with the denatured hTMPK bioreactor, attesting the lack of a false positive. In the case of active hTMPK, dTDP appeared rapidly, after 2 min of infusion (30 s after dTMP accumulation). The plateau conversion was quickly reached after 4 min of dTMP infusion. Compared to the experiment with denatured enzyme, a decrease in dTMP intensity was observed (from 3.8×10^5 a.u for denatured to 1.2×10^5 a.u for active hTMPK) and the plateau was delayed (from 4 to 8 minutes), which confirmed the substrate consumption. The remaining dTMP EIC intensity was not directly correlated to the non-conversion of dTMP into dTDP but it was also due to in-source dTDP fragmentation. This fragmentation could be estimated at 20% by analyzing a range of dTDP concentrations (5-50 μM). The on-line conversion efficiency of dTMP into dTDP was therefore estimated at 67%. Although a decrease in dTMP intensity can be noted (4.3 min, active hTMPK), the feasibility and the non-interference of the switch loop system during valve rotation is proved. This experiment

attested both the feasibility of an on-line phosphorylation and the ability to ensure constant substrate infusion *via* the use of the dual switch loop system developed for this study.

3.2.2. hNDPK bioreactor

To validate the versatility of this method, the hNDPK bioreactor activity was checked by dTDP infusion. As shown in Figure 4, similar results were obtained. The absence of conversion, using denatured hNDPK, attested the lack of false-positive whereas product accumulation (dTTP) was observed with the active bioreactor. Total conversion of dTDP into dTTP was observed. The remaining intensity of dTDP EIC is due to the estimated 50% of dTTP fragmentation. The full conversion is due to the higher V_{\max} value of immobilized hNDPK ($V_{\max(\text{immobilized hNDPK})} = 6.4 \mu\text{L min}^{-1}$ and $V_{\max(\text{immobilized hTMPK})} = 2.9 \mu\text{L min}^{-1}$) that enable a faster conversion. This maximal velocity has an even more important influence on the conversion rate in on-line enzymatic conversion. These experiments proved the feasibility to efficiently (conversion estimation > 60%) and rapidly (< 5 minutes) monitor individual on-line phosphorylation.

3.3. Validation of the on-line approach for multi-step phosphorylation monitoring

On-line individual reactions were shown to be feasible and efficient by the present methodology. The feasibility of the direct monitoring of dTTP accumulation by the on-line multi-step enzymatic reaction was studied, as a proof of concept, by placing the two bioreactors in series in the LC system. The conversion of dTMP into its di- and tri-phosphate form was directly monitored by EIC. Similar conditions to those previously described were applied. Figure 5 shows the EIC of the masses of interest. The initial substrate (dTMP) appeared after 5 min of infusion whereas the accumulation of the intermediate (dTDP) and final products (dTTP) appeared at 10 minutes, reaching a plateau at around 25 minutes. Conversion was shown to be efficient with 55% of dTMP converted into dTTP. The high

intensity of dTMP EIC is due to the limiting step of dTMP conversion into dTDP but also due to the fragmentation of dTDP and dTTP as explained above. The cascade efficiency was consistent with individual reaction efficiencies (55% conversion of dTMP into dTTP for the cascade against 67% and 100 % for each individual bioreactor).

3.4. Bioreactor repeatability and reuse study

The system repeatability and stability were further evaluated. The repeatability of hTMPK and hNDPK bioreactor activities was studied through three successive infusions ($n = 3$) of dTMP (hTMPK bioreactor) and dTDP (hNDPK bioreactor). Relative standard deviations for run-to-run analysis were acceptable with 2.42% for the hTMPK bioreactor and 2.36 % for the hNDPK bioreactor. Longevity was investigated by monitoring bioreactor activities over several days. Figure 6 shows a decrease in normalized bioreactor activities in function of time. The hTMPK bioreactor was still active after 795 minutes, 21 uses and 60 days of storage with a normalized remaining activity of 10%. The hNDPK bioreactor showed better stability with a loss of 60% of the initial activity after 965 minutes, 20 uses and 68 days of storage. The bioreactors can therefore be regenerated after each analysis and can be used for multiple analyses performed over several days. Therefore, a limitation of this methodology could turn out to be the decrease of bioreactor stability over the time. This limitation could be easily overcome with the injection of a reference compound (such as dTMP).

3.5. Application of the on-line methodology: study of ANPs specific conversion regarding hTMPK and $\nu\nu$ TMPK

ANPs have become a key class of antiviral nucleotide derivatives. Following their uptake, ANPs undergo most often two phosphorylation steps catalyzed by cellular kinases to reach their target, the viral DNA polymerase [11]. Concerning the ANPs study, the first phosphorylation step (from MP to DP) is most often described as the rate-limiting step

(compared to DP-TP conversion) [10]. In this context, the developed on-line methodology was applied to the study of the mono-phosphorylation step. The selectivity of antiviral therapy is an important aspect in drug discovery and could have an important impact on pharmacological and toxicological outcomes. One way to design site-selective therapy is the use of viral kinases to convert pro-drug into active nucleoside triphosphate locally in the infected cells. In this work, the feasibility of the on-line monitoring phosphorylation was evaluated for the study of conversion specificity of two ANPs phosphorylations (Figure 1). The ANPs containing a pyrimidine base were proven efficiently activated by viral and human TMPK. The influence of the aliphatic chain length (3, 4 and 5 carbones) and the kind of C₅ substituent was evaluated. hTMPK was shown to efficiently phosphorylate (E)-isomer of allylphosphonate uracil containing a methyl (ANP-CH₃) or a bromine (ANP-Br) at C₅-position whereas vvTMPK exhibited reduced activity towards both substrates [37]. hTMPK and vvTMPK activities regarding ANP-CH₃-MP and ANP-Br-MP were first evaluated by UV-spectrophotometry assay and compared with activities toward the endogenous substrate dTMP. Results are shown in supplementary data Table S1. hTMPK showed high activity regarding the two ANPs with k_{cat}/K_M (ANP-CH₃-MP) = 25 000 M⁻¹ s⁻¹ and k_{cat}/K_M (ANP-Br-MP) = 9 000 M⁻¹ s⁻¹ (respectively 6 and 17 times lower than hTMPK activity regarding dTMP). vvTMPK showed lower activity regarding the same substrates with k_{cat}/K_M (ANP-CH₃-MP) = 1 380 M⁻¹ s⁻¹ and k_{cat}/K_M (ANP-Br-MP) = 1 200 M⁻¹ s⁻¹ (respectively 72 and 83 times lower than vvTMPK activity regarding dTMP).

The proof of concept was developed with the study of the endogenous compound dTMP regarding two human kinase strains TMPK and NDPK. The study proved the feasibility of the on-line method to directly monitor on-line phosphorylation. Two ANPs were then evaluated to study the possible transposition of the method to other substrates (synthesized, with lower

conversion rate) regarding other kinase strains (*vaccina virus*), in order to show the potential of the methodology to realize a screening of various compounds.

The feasibility of the on-line conversions was evaluated by direct infusion of dTMP, ANP-CH₃-MP and ANP-Br-MP into immobilized hTMPK and vvTMPK bioreactors. As vvTMPK shares similar structure with hTMPK [40] the two immobilization processes and efficiencies were considered similar. The monitoring of the specific EIC of masses of interest offered a direct monitoring of the reactions. vvTMPK activity was first validated by a spectrophotometric assay. Results are shown in Table S1.

Figure 7 shows the EIC of interest during dTMP, ANP-CH₃-MP and ANP-Br-MP infusion into active and denatured hTMPK bioreactor. Denatured hTMPK bioreactor gave no conversion for the three substrates which attest to the absence of false positive. As expected with our previous analysis, dTMP conversion was confirmed by infusion into active hTMPK bioreactor. The on-line analyses of ANPs highlighted an accumulation of diphosphate form after 15 min of infusion. Although the catalytic efficiencies of hTMPK regarding ANP-CH₃-MP and ANP-Br-MP respectively were found lower than the catalytic efficiency of dTMP conversion (Table S1), the on-line experiments and immobilized enzymes showed a good correlation with a specific and significant conversion monitoring. Unlike natural substrate, the diphosphate ANP standards are not commercially available. In addition, their ionization disparity and the EIC intensity of diphosphate ANPs cannot be compared to evaluate reaction efficiencies. Although, in this application, this approach is not quantitative, the latter offers various attractive advantages such as a speed of analysis (4 min for dTMP and 15 min of ANPs), a specificity of detection (without a chromatographic dimension), a versatility of analysis (same analytical method for various synthetic compounds) and an identification of the reaction product (HRMS detection) for a better knowledge of phosphorylation mechanism of each drug. To confirm the effectiveness of this methodology, the same ANPs were

analyzed with the *vv*TMPK bioreactor. As shown in Figure 8, *vv*TMPK bioreactor activity was first validated by dTMP infusion. The on-line experiments seem to be correlated with the catalytic efficiency of free *vv*TMPK ($k_{cat}/K_{M(vvTMPK)} = 100\,000\text{ M}^{-1}\text{ s}^{-1}$). Indeed, a significant conversion of dTMP in dTDP was observed. In the case of *vv*TMPK, the dTMP conversion was shown lower. In addition to a lower catalytic efficiency of *vv*TMPK, this lower conversion is likely due to the storage time of the enzyme (hTMPK freshly produced). In case of ANPs infusion into *vv*TMPK bioreactor, the results showed no conversion that attest to the lack of false positive. These results are consistent with the results obtained with the spectrophotometric test (Table S1). In order to improve the confidence of this experiments, the off-line FIA-HRMS methodology was also performed to validate this specificity of conversion. As shown in Figure S5, the on-line monitoring results are also consistent with the off-line FIA-HRMS methodology. These two experiments showed the feasibility of evaluating the activity specificity of the human and *vaccina virus* enzymatic strains regarding two ANP compounds synthesized in the laboratory. These results validated the absence of false positive and/or false negative thus validating the reliability of the on-line method. Indeed, the results obtained with the FIA-HRMS method (off-line sample preparation, time-consuming) with overnight reaction were shown similar to those obtained with the on-line methodology within 15 minutes. This on-line methodology was proved reliable, rapid, automatable and therefore suitable for a screening methodology.

4. Conclusion

This work shows for the first time the feasibility of an on-line MS methodology for the conversion monitoring of nucleoside monophosphate (NMP) into nucleoside diphosphate (NDP) and triphosphate (NTP). As a proof of concept, the two-phosphorylation steps from thymidine monophosphate to thymidine triphosphate were monitored by the methodology.

This dynamic approach showed various attractive advantages such as specificity of detection, speed of analysis (5 minutes), high conversion efficiency (> 50 %), substrate versatility (no chromatographic dimension) and possible automation (for screening methodology). In this context, this work offered an example of application of the on-line methodology for the monitoring of conversion of two Acyclic Nucleoside phosphonates (ANPs) regarding human and *vaccina virus* TMPK strains. This approach was proven reliable regarding the specificity of conversion and results obtained were in agreement with the spectrophotometric and the FIA-HRMS assays. Therefore, thanks to the longevity of bioreactor, the possible automation and multi-step enzymatic monitoring, this methodology could be easily applied to the metabolization study of various new potential antiviral drugs, whether for one step or for multi-step phosphorylation

Although this work was developed by High-Resolution Mass Spectrometry, this methodology is transposable to less expensive mass spectrometers (MRM mode). Actually, this development can be applied to the study of other synthetic (pro)drugs in order to bring better comprehension of a potential drug metabolic pathway: phosphorylation steps, specific activity regarding human or viral enzymatic strains....

ACKNOWLEDGMENTS: LAA thanks Dr C El Amri and Dr D. Deville-Bonne of University Pierre et Marie Curie (UPMC, Paris, France) for the generous gift of nucleoside/nucleotide kinases and their plasmids. JF thanks the **Région Centre-Val de Loire** for a PhD scholarship. We thank the LABEX SynOrg (ANR-11-LABX-0029) for partial financial support.

419

420

421

422
423
424
425
426
427
428
429
430
431
432
433
434
435
436

[1] G.N. Kumar, S. Surapaneni, Role of drug metabolism in drug discovery and development, *Med Res Rev.* 5 (2001) 397-411.

[2] G. Apic, T. Ignjatovic, S. Boyer, R.B. Russel, Illuminating drug discovery with biological pathways, *Minireview* 579 (2005) 1872-1877.

[3] D. Topalis, R. Snoeck, G. Andrei, , Tenofovir activating kinases may impact the outcome of HIV treatment and prevention, *Ebiomedicine* 2 (2015) 1018-1019.

[4] T. Cihlar, A.S. Ray, Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine, *Antiviral Res.* 85(1) (2010) 39-58.

[5] J. Bourdais, R. Biondi, S. Sarfati, C. Guerreiro, L. Lascu, J. Janin, M. Véron, Cellular Phosphorylation of anti-HIV nucleosides, *J. Biol. Chem* 271(14) (1996) 7887-7890.

[6] E. De Clercq, Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster, *Biochem Pharmacol* 68(12) (2004) 2301-15.

[7] E. De Clercq, A. Holy, Acyclic nucleoside phosphonates: a key class of antiviral drugs, *Nat. Rev. Drug Discov.* 4 (2005) 928-940.

[8] R.J. Whitley, Drug discovery for human immunodeficiency virus infection: conquests and hurdles, *J. Antimicrob. Chemother.* 37 (1996) 151-159.

[9] M. Baba, R. Pauwels, P. Herdewijn, E. De Clercq, J. Desmyter, M. Vandeputte, Both 2', 3'-dideoxythymidine and its 2', 3'-unsaturated derivative (2', 3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro, *Biochem. Biophys. Res. Commun* 142 (1987) 128-134.

[10] A. Lavie, M. Konrad, Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase, *J. Med. Chem.* 4 (2004) 351-359.

[11] D. Deville-Bonne, C. El Amri, P. Meyer, Y. Chen, L.A. Agrofoglio, J. Janin, Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties, *Antiv. Res.* 86(1) (2010) 101-20.

[12] A.R. Van Rompay, M. Johansson, A. Karlsson, Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases, *Pharmacol. Ther* 100(2) (2003) 119-139.

465 [13] E. De Clerq, Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines., *Methods Find*
 466 *Exp Clin Pharmacol.* 2 (1980) 253-267.

467 [14] Y. Zhang, Y. Gao, X. Wen, H. Ma, Current prodrug strategies for improving oral absorption of
 468 nucleoside analogues, *AJPS* 9(2) (2014) 65-74.

469 [15] F. Pertusati, S. Serafini, N. Albadry, R. Snoeck, G. Andrei, Phosphonoamidate prodrugs of C5-
 470 substituted pyrimidine acyclic nucleosides for antiviral therapy, *Antiv. Res.* 143 (2017) 262-268.

471 [16] A. Varga, E. Graczer, L. Chaloin, K. Liliom, P. Zavodszky, C. Lionne, M. Vas, Selectivity of kinases
 472 on the activation of tenofovir, an anti-HIV agent, *Eur J Pharm Sci.* 48(1-2) (2013) 307-15.

473 [17] C. Blondin, L. Serina, L. Wiesmüller, A.M Gilles, O. Bârz, Improved spectrophotometric assay of
 474 nucleoside monophosphate kinase activity using the pyruvate kinase/lactate dehydrogeanse coupling
 475 system, *Anal. Chem.* 220 (1994) 219-221.

476 [18] R.M. Lilley, D.A. Walker, An improved spectrophotometric assay for ribulosebisphopshate
 477 carboxylase, *Biochim. Biophys. Acta* 358 (1974) 226-229.

478 [19] P. Schelling, G. Folkers, L. Scapozza, A spectrophotometric assay for quantitative determination
 479 of kcat of herpes simplex virus type 1 thymidine kinase substrates, *Anal. Biochem.* 295(1) (2001) 82-
 480 7.

481 [20] B. N. Stretcher, A. J. Pesce, P. T. Frame, D. S. Stein, Pharmacokinetics of Zidovudine
 482 Phosphorylation in Peripheral Blood Mononuclear Cells from Patients Infected with Human
 483 Immunodeficiency Virus, *Antimicrob. Agents Chemother.*, 38 (1994) 1541-1547.

484 [21] R. R. Drake, T. N. Wilbert, T. A. Hinds, K. M. Gilbert, Differential ganciclovir-mediated cell killing
 485 by glutamine 125 mutants of herpes simplex virus type 1thymidine kinase, *J. Biol. Chem.* 274 (1999)
 486 37186-37192.

487 [22] I. G. Giles, P. C. Poat, K. A. Munday, The kinetics of rabbit muscle pyruvate kinase, *Biochem. J.*
 488 157 (1976) 577-589.

489 [23] M. Faria, M.S. Halquist, E. Kindt, W. Li, H.T. Karnes, P.J. O'Brien, Liquid chromatography-tandem
 490 mass spectrometry method for quantification of thymidine kinase activity in human serum by
 491 monitoring the conversion of 3'-deoxy-3'-fluorothymidine to 3'-deoxy-3'-fluorothymidine
 492 monophosphate, *J Chromatogr B Analyt Technol Biomed Life Sci* 907 (2012) 13-20.

493 [24] C.C. Liu, J.S. Huang, D.L. Tyrrell, N.J. Dovichi, Capillary electrophoresis-electrospray-mass
 494 spectrometry of nucleosides and nucleotides: application to phosphorylation studies of anti-human
 495 immunodeficiency virus nucleosides in a human hepatoma cell line, *Electrophoresis* 26(7-8) (2005)
 496 1424-31.

497 [25] Y. Qi, Y. Li, J.J. Bao, Development of a capillary electrophoresis method for analyzing adenosine
 498 deaminase and purine nucleoside phosphorylase and its application in inhibitor screening, *Anal.*
 499 *Biochem.* 506 (2016) 31-44.

500 [26] H.F. Tzeng, H.P. Hung, Simultaneous determination of thymidylate and thymidine diphosphate
 501 by capillary electrophoresis as a rapid monitoring tool for thymidine kinase and thymidylate kinase
 502 activities, *Electrophoresis* 26(11) (2005) 2225-30.

503 [27] L. Zhu, L. Chen, H. Luo, X. Xu, Frontal Affinity Chromatography Combined On-Line with Mass
 504 Spectrometry: A Tool for the Binding Study of Different Epidermal Growth Factor Receptor
 505 Inhibitors, *Anal. Chem.* 75 (2003) 6388-6393.

506 [28] E. Calleri, C. Temporini, G. Massolini, Frontal affinity chromatography in characterizing
 507 immobilized receptors, *J. Pharm. Biomed. Anal* 54(5) (2011) 911-925.

508 [29] E. Calleri, C. Temporini, B. Caccianlanza, G. Massolini, Target-Based Drug Discovery: the
 509 Emerging Success of Frontal Affinity Chromatography Coupled to Mass Spectrometry,
 510 *ChemMedChem* 4 (2009) 905-916.

511 [30] X. Song, J. Cui, J. Li, H. Yan, L. Li, L. Wen, Y. Geng, D. Wang, A novel bioreactor for highly efficient
 512 biotransformation of resveratrol from polydatin with high-speed counter-current chromatography,
 513 *LWT* 103 (2019) 192-198.

514 [31] J. Guo, H. Lin, J. Wang, Y. Lin, T. Zhang, Z. Jiang, Recent advances in bio-affinity chromatography
 515 for screening bioactive compounds from natural products, *J Pharm Biomed Anal* 165 (2019) 182-197.

- [32] T. Slechtova, M. Gilar, K. Kalikova, S.M. Moore, J.W. Jorgenson, E. Tesarova, Performance comparison of three trypsin columns used in liquid chromatography, *J. Chrom. A* 1490 (2017) 126-132.
- [33] K.I. Kasai, Y. Oda, M. Nishikata, S.I. Ishii, Frontal affinity chromatography: Theory for its application to studies on specific interactions of biomolecules, *J. Chrom. B Biomed Sci Appl* 376 (1986) 33-47.
- [34] H.C. Foo, N.W. Smith, S.M. Stanley, Fabrication of an on-line enzyme micro-reactor coupled to liquid chromatography-tandem mass spectrometry for the digestion of recombinant human erythropoietin, *Talanta* 135 (2015) 18-22.
- [35] S. Bhattacharya, M. Schiavone, J. Gomes, S.K. Bhattacharya, Cascade of bioreactors in series for conversion of 3-phospho-D-glycerate into D-ribulose-1,5-bisphosphate: kinetic parameters of enzymes and operation variables, *J. Biotechnol.* 111(2) (2004) 203-17.
- [36] J. Yin, T. Xu, N. Zhang, H. Wang, Three-Enzyme Cascade Bioreactor for Rapid Digestion of Genomic DNA into Single Nucleosides, *Anal. Chem.* 88(15) (2016) 7730-7.
- [37] D. Topalis, U. Pradere, V. Roy, C. Caillat, A. Azzouzi, J. Broggi, R. Snoeck, G. Andrei, J. Lin, S. Eriksson, J.A. Alexandre, C. El-Amri, D. Deville-Bonne, P. Meyer, J. Balzarini, L.A. Agrofoglio, Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates, *J Med Chem* 54(1) (2011) 222-32.
- [38] S. Pochet, L. Dugue, G. Labesse, M. Delepierre, H. Munier-Lehmann, Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of *Mycobacterium tuberculosis* and of humans, *Chembiochem* 4(8) (2003) 742-7.
- [39] J. Ferey, D. Da Silva, C. Colas, R. Nehmé, P. Lafite, V. Roy, P. Morin, R. Daniellou, L. Agrofoglio, B. Maunit, Monitoring of successive phosphorylations of thymidine using free and immobilized human nucleoside/nucleotide kinases by Flow Injection Analysis with High-Resolution Mass Spectrometry, *Anal. Chim. Acta* (2018).
- [40] C. Caillat, D. Topalis, L.A. Agrofoglio, S. Pochet, J. Balzarini, D. Deville-Bonne, P. Meyer, Crystal structure of poxvirus thymidylate kinase: an unexpected dimerization has implications for antiviral therapy, *Proc Natl Acad Sci USA* 105(44) (2008) 16900-5.

Figure captions

Figure 1: Chemical formula of (a) Acyclic Nucleoside Phosphonate-CH₃ (ANP-CH₃-MP) and (b) Acyclic Nucleoside Phosphonate-Br (ANP-Br-MP).

Figure 2: On-line experiment methodology; 2 sample loops of 320 µL connected to the two bioreactors in series via a 10-port valve. The bioreactors are directly connected to the high-resolution mass spectrometer via an electrospray source. The autosampler injects a solution “1” in the loop 1 (position valve 1-2) with the loading pump. The valve switches to position 1-10 to infuse solution “1” into the bioreactors with the analytical pump. During solution “1” infusion, a solution “2” is loaded into the loop 2 with the loading pump (position valve 1-10). When the infusion is completed (time infusion programmed in the method), the valve switches to position 1-2 and loop 2 is infused with the analytical pump.

Figure 3: hTMPK bioreactor; monitoring of EIC for dTMP and dTDP (m/z 321.0500 $[M-H]^-$ for dTMP, m/z 401.0166 $[M-H]^-$ for dTDP) for (a) denatured and (b) active bioreactors. $[dTMP] = 20 \mu M$ ($[ATP] = 150 \mu M$, $[MgCl_2] = 200 \mu M$), flow rate = $60 \mu L \min^{-1}$, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch every 3 minutes.

Figure 4: hNDPK bioreactor; monitoring of EIC for dTDP and dTTP (m/z 401.0166 $[M-H]^-$ for dTDP and m/z 480.9831 $[M-H]^-$ for dTTP) for (a) denatured and (b) active bioreactors. $[dTDP] = 20 \mu M$ ($[ATP] = 150 \mu M$, $[MgCl_2] = 200 \mu M$), flow rate = $40 \mu L \min^{-1}$, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch: 5 minutes.

Figure 5: enzymatic cascade; monitoring of EIC for dTMP, dTDP and dTTP (m/z 321.0500 $[M-H]^-$ for dTMP, m/z 401.0166 $[M-H]^-$ for dTDP and m/z 480.9831 $[M-H]^-$ for dTTP) for (a) denatured and (b) active bioreactors. $[dTMP] = 20 \mu M$ ($[ATP] = 150 \mu M$, $[MgCl_2] = 200 \mu M$), flow rate = $40 \mu L \min^{-1}$, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch: 5 minutes.

Figure 6: stability of bioreactors. Conversion efficiency: hTMPK was used 21 times (795 minutes, $37^\circ C$) over 60 days (diamonds) and hNDPK was used 20 times (915 minutes, $37^\circ C$) over 68 days (squares).

Figure 7: Active and denatured hTMPK bioreactor; monitoring of EIC for dTMP (m/z 321.0500), ANP-CH₃-MP (m/z 259.0562) and ANP-Br-MP (m/z 322.0561) conversion into dTMP (m/z 401.0166), ANP-CH₃-DP (m/z 339.0150) and ANP-Br-DP (m/z 402.0149). Solution of $20 \mu M$ of each substrate ($[MgCl_2] = 200 \mu M$, $[ATP] = 150 \mu M$, 50 mM AcNH₄, pH = 7). Flow rate = $60 \mu L \min^{-1}$.

Figure 8: Active vvTMPK bioreactor; monitoring of EIC for dTMP (m/z 321.0500), ANP-CH₃-MP (m/z 259.0562) and ANP-Br-MP (m/z 322.0561) conversion into dTMP (m/z 401.0166), ANP-CH₃-DP (m/z 339.0150) and ANP-Br-DP (m/z 402.0149). Solution of $20 \mu M$ of each substrate ($[MgCl_2] = 200 \mu M$, $[ATP] = 150 \mu M$, 50 mM AcNH₄, pH = 7). Flow rate = $60 \mu L \min^{-1}$.

611

612 **Table captions**

613

614 **Table 1:** m/z values of Thymidine Monophosphate (dTMP), Thymidine Diphosphate (dTDP),
615 Thymidine Triphosphate (dTTP), methyl allylphosphonate uracil (ANP-CH₃) and bromine
616 allylphosphonate uracil (ANP-Br).

617

618

619

620

621

622

623




Figure 1: Chemical formula of (a) Acyclic Nucleoside Phosphonate-CH₃ (ANP-CH₃-MP) and (b) Acyclic Nucleoside Phosphonate-Br (ANP-Br-MP).




Figure 2: On-line experiment methodology; 2 sample loops of $320\ \mu\text{L}$ connected to the two bioreactors in series via a 10-port valve. The bioreactors are directly connected to the high-resolution mass spectrometer via an electrospray source. The autosampler injects a solution "1" into the loop 1 (position valve 1-2) with the loading pump. The valve switches to position 1-10 to infuse solution "1" into the bioreactors with the analytical pump. During solution "1" infusion, a solution "2" is loaded into the loop 2 with the loading pump (position valve 1-10). When the infusion is completed (time infusion programmed in the method), the valve switches to position 1-2 and loop 2 is infused with the analytical pump.




Figure 3: hTMPK bioreactor; monitoring of EIC for dTMP and dTDP (m/z 321.0500 [M-H]⁻ for dTMP, m/z 401.0166 [M-H]⁻ for dTDP) for (a) denatured and (b) active bioreactors. [dTMP] = 20 μ M ([ATP] = 150 μ M, [MgCl₂] = 200 μ M), flow rate = 60 μ L min⁻¹, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch every 3 minutes.




Figure 4: hNDPK bioreactor; monitoring of EIC for dTDP and dTTP (m/z 401.0166 [M-H] $^-$ for dTDP and m/z 480.9831 [M-H] $^-$ for dTTP) for (a) denatured and (b) active hNDPK. [dTDP] = 20 μ M ([ATP] = 150 μ M, [MgCl₂] = 200 μ M), flow rate = 40 μ L min $^{-1}$, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch: 5 minutes.




Figure 5: enzymatic cascade; monitoring of EIC for dTMP, dTDP and dTTP (m/z 321.0500 [M-H]⁻ for dTMP, m/z 401.0166 [M-H]⁻ for dTDP and m/z 480.9831 [M-H]⁻ for dTTP) for (a) denatured and (b) active bioreactors. [dTMP] = 20 μ M ([ATP] = 150 μ M, [MgCl₂] = 200 μ M), flow rate = 40 μ L min⁻¹, mobile phase: ammonium acetate buffer (50 mM, pH = 7). Valve switch: 5 minutes.




Figure 6: stability of bioreactors. Conversion efficiency: hTMPK was used 21 times (795 minutes, 37°C) over 60 days (diamonds) and hNDPK was used 20 times (915 minutes, 37°C) over 68 days (squares).




Figure 7: Active and denatured hTMPK bioreactor; monitoring of EIC for dTMP (m/z 321.0500), ANP-CH₃-MP (m/z 259.0562) and ANP-Br-MP (m/z 322.0561) conversion into dTMP (m/z 401.0166), ANP-CH₃-DP (m/z 339.0150) and ANP-Br-DP (m/z 402.0149). Solution of 20 μ M of each substrate ([MgCl₂] = 200 μ M, [ATP] = 150 μ M, 50 mM AcNH₄, pH = 7). Flow rate = 60 μ L min⁻¹.




Figure 8: Active $\nu\nu$ TMPK bioreactor; monitoring of EIC for dTMP (m/z 321.0500), ANP-CH₃-MP (m/z 259.0562) and ANP-Br-MP (m/z 322.0561) conversion into dTMP (m/z 401.0166), ANP-CH₃-DP (m/z 339.0150) and ANP-Br-DP (m/z 402.0149). Solution of 20 μ M of each substrate ($[MgCl_2] = 200 \mu$ M, $[ATP] = 150 \mu$ M, 50 mM AcNH₄, pH = 7). Flow rate = 60 μ L min⁻¹.

Endogenous				
[M-H] ⁻	dTMP	dTDP	dTTP	
<i>m/z</i>	321.0500	401.0166	480.9831	
ANPs				
[M-H] ⁻	ANP-CH ₃ -MP	ANP-CH ₃ -DP	ANP-Br-MP	ANP-Br-DP
<i>m/z</i>	259.0562	339.0150	322.0561	402.0149

Table 1: *m/z* values of Thymidine Monophosphate (dTMP), Thymidine Diphosphate (dTDP), Thymidine Triphosphate (dTTP), methyl allylphosphonate uracil (ANP-CH₃) and bromine allylphosphonate uracil (ANP-Br).

